Royalty Pharma (STU:RPD) Marketable Securities : €674 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Royalty Pharma Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Royalty Pharma's Marketable Securities for the quarter that ended in Mar. 2025 was €674 Mil.

Royalty Pharma's annual Marketable Securities increased from Dec. 2022 (€677 Mil) to Dec. 2023 (€694 Mil) and increased from Dec. 2023 (€694 Mil) to Dec. 2024 (€804 Mil).

Royalty Pharma Marketable Securities Historical Data

The historical data trend for Royalty Pharma's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Marketable Securities Chart

Royalty Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Marketable Securities

Get a 7-Day Free Trial

1,348.46

1,117.07

676.89

693.93

804.08

Royalty Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Marketable Securities	Get a 7-Day Free Trial															634.32	732.61	733.66	804.08	674.01

Royalty Pharma Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Royalty Pharma (STU:RPD) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Royalty Pharma Marketable Securities Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Royalty Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (STU:RPD) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

RPRX:USA RPRX:Mexico

Address

110 East 59th Street, New York, NY, USA, 10022

Website

https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.